Essential Thrombocythemia — Variants & evidence

Essential Thrombocythemia — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

5 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 1–5 of 5 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CALR EXON 9 FRAMESHIFT3
(prognostic)	Prognostic	B	Supports Better Outcome	3	submitted	EID6387 In a study of 402 patients with essential thrombocythemia, 227 harbored JAK2 mutations and 114 harbored CALR mutations (51 type 1 L367fs46 and 44 type 2 K385fs47). Overall survival did not differ be… (full text at CIViC) PMID 24753125 · Tefferi et al., 2014 · Open in CIViC	civic
〃	Prognostic	B	Does Not Support Poor Outcome	2	submitted	EID6389 In the subset of patients with essential thrombocythemia (including potential unidentified prefibrotic stage of myelofibrosis), patients with type 1 L367fs*46 mutations (N=111) had no significant diff… (full text at CIViC) PMID 25212275 · Cabagnols et al., 2015 · Open in CIViC	civic
Peginterferon Alfa-2a	Predictive	B	Supports Sensitivity Response	4	accepted	EID1482 Study explored the hematologic and molecular responses in a cohort of 31 patients presenting with thrombocythemia and CALR exon 9 frameshift mutations. All 31 patients exhibited a hematologic response… (full text at CIViC) PMID 26486786 · Verger et al., 2015 · Open in CIViC	civic
CALR Mutation1
(diagnostic)	Diagnostic	A	Supports Positive	5	accepted	EID6382 Diagnostic criterion for essential thrombocytemia according to the World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues 2016. PMID 27069254 · Arber et al., 2016 · Open in CIViC	civic
MPL Mutation1
(diagnostic)	Diagnostic	A	Supports Positive	5	submitted	EID6383 Diagnostic criterion for essential thrombocytemia according to the World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues 2016. PMID 27069254 · Arber et al., 2016 · Open in CIViC	civic

Data updated 2 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.